Pharsight

Avastin patents expiration

List of large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US6054297 GENENTECH, INC. Humanized antibodies and methods for making them
Feb, 2018

(6 years ago)

US9795672 GENENTECH, INC. Treatment with anti-VEGF antibodies
May, 2024

(30 days from now)

US7485704 GENENTECH, INC. Reducing protein A leaching during protein A affinity chromatography
Mar, 2025

(10 months from now)

US10906986 GENENTECH, INC. Prevention of disulfide bond reduction during recombinant production of polypeptides
Jul, 2028

(4 years from now)

US11078294 GENENTECH, INC. Prevention of disulfide bond reduction during recombinant production of polypeptides
Jul, 2028

(4 years from now)

US8460895 GENENTECH, INC. Method for producing recombinant proteins with a constant content of pCO2 in the medium
Mar, 2029

(4 years from now)

US9714293 GENENTECH, INC. Production of proteins in glutamine-free cell culture media
Aug, 2030

(6 years from now)

US10982003 GENENTECH, INC. Production of proteins in glutamine-free cell culture media
Aug, 2030

(6 years from now)

US8512983 GENENTECH, INC. Production of proteins in glutamine-free cell culture media
Jan, 2031

(6 years from now)

US10662237 GENENTECH, INC. Method to improve virus filtration capacity
May, 2031

(7 years from now)

US10011856 GENENTECH, INC. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
May, 2031

(7 years from now)

US10704071 GENENTECH, INC. Decreasing lactate level and increasing polypeptide production by down regulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
Aug, 2031

(7 years from now)

US9487809 GENENTECH, INC. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
Jan, 2032

(7 years from now)

US10513697 GENENTECH, INC. CO2 profile cultivation
Sep, 2032

(8 years from now)

US10906934 GENENTECH, INC. Protein purification methods
Oct, 2033

(9 years from now)

US10676710 GENENTECH, INC. Cell culture compositions with antioxidants and methods for polypeptide production
Mar, 2034

(9 years from now)

US9441035 GENENTECH, INC. Cell culture media and methods of antibody production
Apr, 2034

(9 years from now)

US10274466 GENENTECH, INC. Elucidation of ion exchange chromatography input optimization
Jul, 2035

(11 years from now)

US10208355 GENENTECH, INC. Method of treatment for glioblastoma by administering a VEGF antagonist
Jul, 2035

(11 years from now)

US10336983 GENENTECH, INC. Method for increasing the specific production rate of eukaryotic cells
Jul, 2035

(11 years from now)

Ingredients: RECOMBINANT HUMANIZED MONOCLONAL IGG1 ANTIBODY